S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
10 Best Airline Stocks to Buy
What is a Growth Stock Mutual Fund?
The Real Problem With "Made in America" Lithium (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Netflix Collaboration Fuels IAS, DoubleVerify Stock Surge
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
10 Best Airline Stocks to Buy
What is a Growth Stock Mutual Fund?
The Real Problem With "Made in America" Lithium (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Netflix Collaboration Fuels IAS, DoubleVerify Stock Surge
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
10 Best Airline Stocks to Buy
What is a Growth Stock Mutual Fund?
The Real Problem With "Made in America" Lithium (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Netflix Collaboration Fuels IAS, DoubleVerify Stock Surge
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Global shares trade mixed following technology selloff on Wall Street
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
10 Best Airline Stocks to Buy
What is a Growth Stock Mutual Fund?
The Real Problem With "Made in America" Lithium (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Apple Partnership Strengthens Unity Software's Investment Appeal
Netflix Collaboration Fuels IAS, DoubleVerify Stock Surge

Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price & News

$7.38
+0.15 (+2.07%)
(As of 06/7/2023 ET)
Compare
Today's Range
$7.24
$7.43
50-Day Range
$7.19
$9.47
52-Week Range
$6.78
$11.44
Volume
21.98 million shs
Average Volume
18.87 million shs
Market Capitalization
$8.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
44.5% Upside
$10.67 Price Target
Short Interest
Healthy
1.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.39%
From $2.19 to $2.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

438th out of 981 stocks

Pharmaceutical Preparations Industry

195th out of 467 stocks


TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
8-K: TEVA PHARMACEUTICAL INDUSTRIES LTD
See More Headlines

TEVA Price History

TEVA Company Calendar

Last Earnings
5/10/2023
Today
6/08/2023
Next Earnings (Estimated)
7/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
36,826
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+44.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

Net Income
$-2,353,000,000.00
Pretax Margin
-15.76%

Debt

Sales & Book Value

Annual Sales
$14.93 billion
Cash Flow
$3.69 per share
Book Value
$7.82 per share

Miscellaneous

Outstanding Shares
1,120,410,000
Free Float
1,111,219,000
Market Cap
$8.27 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Richard Francis
    President, Chief Executive Officer & Director
  • Eric DrapéEric Drapé
    Executive Vice President-Global Operations
  • Eli Kalif
    Chief Financial Officer & Executive Vice President
  • Eric A. Hughes
    Chief Medical Officer, Executive VP-Global R&D
  • Kathleen Veit
    Senior VP-Global Compliance & Ethics Officer













TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2023?

10 Wall Street analysts have issued 1 year target prices for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $14.00. On average, they predict the company's share price to reach $10.67 in the next year. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2023?

Teva Pharmaceutical Industries' stock was trading at $9.12 at the beginning of 2023. Since then, TEVA shares have decreased by 19.1% and is now trading at $7.38.
View the best growth stocks for 2023 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decline in short interest in April. As of April 30th, there was short interest totaling 12,730,000 shares, a decline of 16.6% from the April 15th total of 15,260,000 shares. Based on an average trading volume of 8,860,000 shares, the short-interest ratio is presently 1.4 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our TEVA earnings forecast
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Wednesday, May, 10th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.55 by $0.18. The company earned $3.66 billion during the quarter, compared to analyst estimates of $3.60 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 27.58% and a negative net margin of 10.73%.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $2.25-$2.55 for the period, compared to the consensus estimate of $2.40. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.06 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.62%), Migdal Insurance & Financial Holdings Ltd. (2.10%), Harel Insurance Investments & Financial Services Ltd. (2.10%), State Street Corp (1.76%), Clal Insurance Enterprises Holdings Ltd (1.70%) and Exor Capital LLP (1.54%). Insiders that own company stock include David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $7.38.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $8.27 billion and generates $14.93 billion in revenue each year. The company earns $-2,353,000,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 36,826 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -